Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder

Eligibility Criteria

• * Participants has provided signed, informed consent before initiation of any study specific procedures
• * Aged ≥18 years at the time of signing the informed consent
• * Confirmed P/LP germline RUNX1 variant per ClinGen Myeloid Malignancy Variant Curation Expert Panel (MM-VCEP) RUNX1-specific variant curation rules80
• * Participants must be willing to provide bone marrow sample at time of screening and at the end of treatment with sirolimus
• * Platelet count of ≥50,000/µL
• * Adequate renal function: estimated glomerular filtration rate based on Modification of Diet in Renal Disease (MDRD) calculation, \>30 mL/min/1.73m2
• * Adequate hepatic function: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \<3 × upper limit of normal (ULN) and total bilirubin \<1.5 × ULN
• * Adequate cardiac function: left ventricular ejection fraction \>50%
• * Known allergy to sirolimus
• * History of lymphoma or other hematologic malignancies
• * Uncontrolled bleeding
• * Any prior diagnosis of myelodysplastic syndrome or other hematologic malignancy using International Working Group criteria
• * Prior treatment with sirolimus or a rapalog, mTOR inhibitor, or B-cell-depleting therapy within 28 days before study day 1
• * Treatment with strong inhibitors of cytochrome P450 3A4 (CYP3A4; eg, ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin, and clarithromycin), strong inducers of CYP3A4 (eg, rifampin and rifabutin), other drugs that could increase sirolimus blood concentrations (eg, bromocriptine, cimetidine, cisapride, clotrimazole, danazol, diltiazem, fluconazole, letermovir, protease inhibitors \[eg, ritonavir, indinavir, boceprevir, and telaprevir\], metoclopramide, nicardipine, troleandomycin, and verapamil), other drugs that could decrease sirolimus blood concentrations (eg, carbamazepine, phenobarbital, phenytoin, rifapentine, St. John's Wort \[Hypericum perforatum\]), or drugs with blood concentrations that could increase (eg, verapamil) within 7 days before study day 1
• * Use of cannabidiol, which can increase blood levels of sirolimus, within 7 days before study day 1
• * Myocardial infarction within 6 months before study day 1, congestive heart failure (New York Heart Association \> class II)
• * Total cholesterol \>300 mg/dL or triglyceride \>400 mg/dL
• * Arterial thrombosis (eg, stroke or transient ischemic attack) within 6 months before study day 1
• * Infection requiring intravenous anti-infective treatment within 1 week of study day 1
• * Live vaccines (eg, measles, mumps, rubella, oral polio, BCG, yellow fever, varicella, and TY21a typhoid) within 28 days before study day 1
• * Known diagnosis of chronic viral infection (eg, hepatitis B or C or HIV, and Epstein-Barr) or tuberculosis
• * Women who are pregnant, may become pregnant, or who are breastfeeding